Navigation Links
AACR news: New target plus new drug equals death of melanoma cells
Date:4/9/2013

Collaborative research presented by the University of Colorado Cancer Center, the University of North Carolina at Chapel Hill, Harvard Medical School and the University of Pittsburgh, at the American Association for Cancer Research (AACR) Annual Conference, shows that the protein receptor Mer is overexpressed in melanoma and that the investigational drug UNC1062 blocks Mer survival signaling in these cells, killing them.

"It's exciting in that Mer receptor expression correlates so perfectly with disease progression. It's tiered you see a bump in expression as you transition from nevus to melanoma and then again as you transition from melanoma to metastatic disease," says Doug Graham, MD, PhD, investigator at the CU Cancer Center and associate professor of Pediatrics and Immunology at the University of Colorado School of Medicine, the paper's senior author.

After proving this correlation between Mer receptor expression and disease stage in melanoma tissues from clinical patient samples, Graham and colleagues wondered what would happen if they interrupted this Mer signaling. Luckily, the University of North Carolina had recently developed a new compound that did just that UNC1062. The results were dramatic.

"We showed decreased survival signaling, increased apoptosis and decreased growth of the melanoma cells in dishes and in mouse models," Graham says. It seems that Mer receptors are not only correlated with melanoma progression but are in fact driving the aggressiveness of the disease.

"This is the first time there's been an association between Mer and melanoma and the first time to report about this new drug," Graham says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
805-559-2023
University of Colorado Denver
Source:Eurekalert

Page: 1

Related biology news :

1. Good news: Fewer maternal and child deaths
2. REACH news: European ombudsman takes up PETA complaint
3. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
4. AACR news: Six2 homeoprotein allows breast cancer cells to detach and metastasize
5. AACR news: Little molecule makes big difference in bladder cancer metastasis
6. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
7. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
8. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
9. Nanobubbles plus chemotherapy equals single-cell cancer targeting
10. Researchers identify Achilles heel of dengue virus, target for future vaccines
11. Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... 2, 2017 Summary This report provides ... its partnering interests and activities since 2010. ... Read the full report: ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ...
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader ... its elite iris biometric solution on the latest ... LTE at Mobile World Congress 2017 (February ... Booth in Hall 3, Stand 3E10. ... Qualcomm Haven™ security platform—a combination of hardware, ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... Bactana Animal ... hormones in the world’s food supply through enhancement of the gut microbiota, today announced ... included Connecticut Innovations , New York-based Sustainable Income Capital Management, LLC and a ...
(Date:3/29/2017)... and NEWARK, Del. , March 29, ... regenerative medicine company, and W. L. Gore ... today announced a collaborative research agreement whereby the two ... therapy delivery device technologies that provide protection from immune ... ViaCyte has been developing innovative stem cell-derived cell replacement ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ -  GeneNews Limited (TSX:GEN) ... BreastSentry™ , a new risk stratification test for breast cancer, ... Innovative Diagnostics Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker test ... lifetime risk for developing breast cancer.   ... BreastSentry measures the fasting ...
(Date:3/29/2017)... The Global Microfluidic Chips Market by Manufacturers, Countries, Type ... study on the existing state of the global Microfluidic Chips industry ... and Asia-Pacific , South ... Africa . ... Browse 172 Tables and Figures, 13 Major Company Profiles, spread ...
Breaking Biology Technology: